Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7152157 | 1.00 | KMT2A (0.68) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL30487448 | 0.92 | KMT2A (0.73) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL7146326 | 0.92 | KMT2A (0.58) | KMT2APOLBSMN1; SMN2 | |
| SCHEMBL7551114 | 0.92 | KMT2A (0.58) | KMT2APOLBSMN1; SMN2 | |
| SCHEMBL10788732 | 0.90 | KMT2A (0.65) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL10788724 | 0.90 | KMT2A (0.65) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL29359618 | 0.90 | KMT2A (0.78) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL31186018 | 0.90 | KMT2A (0.78) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL10794138 | 0.88 | KMT2A (0.62) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL10794129 | 0.88 | KMT2A (0.62) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173452-A1 | Cytostatic-glycoconjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002051862-A2 | CYTOSTATIC-GLYCOCONJUGATES HAVING SPECIFICALLY CLEAVABLE PEPTIDICLINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219634-A1 | Cytostatic-glycoconjugates having specifically cleavable peptidic linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173452-A1 | Cytostatic-glycoconjugates having specifically cleavable linking units | CTSE, CTSL, CTSZ | KMT2A 3269/4885POLB 2127/4885SMN1; SMN2 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.